Senhwa CX-5461 is designed for inhibition of DNA damage response (DDR) of cancer cell and its novelty of mechanism has shown great potential in cancer treatment. CX-5461 phase I data in Hematological malignancies treatment has been accepted and will be presented at the 59th American Society of Hematology (ASH) annual meeting on 11th December. With the outstanding development progress of CX-5461, Senhwa has been chosen as “2017 BioTaiwan Highlight Benchmark Company” by the Institute for Biotechnology and Medicine Industry (IBMI).
The 59th ASH Annual Meeting will be held in Atlanta, the United States on December 9-12. Senhwa’s clinical partner - Peter MacCallum Cancer Center, PMCC, Australia was invited and expected to hold poster presentation of CX-5461 phase I data in Hematological Cancer treatment. CX-5461 has demonstrated favorable safety and potential in Hematological cancer. John Soong, the Chief Medical Officer of Senhwa was the co-author of the clinical report and it will also be published in “Blood”, the medical journal of ASH on December 8.
In addition to publication abroad, CX-5461’s clinical approach of synthetic lethality was admired and published in Taiwan Medical Journal in October, the largest-circulation of publication among the medical community and it reached more than 46,000 doctor readership in Taiwan. The author is Dr. King-Jen Chang, professor of the Department of surgery at National Taiwan University, also the founder and chairman of the Foundation of Breast Cancer Prevention and Treatment. The theme of article is: The novel resolution of cancer treatment- the application of synthetic lethality. Dr. Chang commented that CX-5461 is designed to stabilize DNA G-quadruplexes of cancer cell and lead to replication fork stalling. While acting in concert with HR pathway deficiency, such as BRCA1/2 mutations, which stalls replication forks undergo DNA breaks and causes cancer cell death. CX-5461 in combination with HRD tumors may be exploited through a synthetic lethality approach targeting DNA repair defects in HRD tumors. Dr. Chang wrote that he was thrilled to see the novelty of CX-5461 developed by a Taiwanese company and hoped that CX-5461 will become rescue medication for PARP inhibitor-resistant patients, which is in line with the current mainstream of DDR research and development for anticancer drugs.
Through the incessantly effort in drug development, Senhwa is selected as “2017 BioTaiwan Highlight Benchmark Company” by IBMI and this award is issued once in 2 years in Taiwan. The indicators of selection include development progress, patent layout, corporate strategy and so on. Only 42 award winners including Senhwa, chosen from 279 nominated companies, will be introduced in English and published in the brochure of "2017 BioTaiwan Highlights". The organizer, IBMI hopes to actively introduce and bring these excellent companies to the world.